leisure time -WSS

leisure time

author：explore 2025-09-27 15:59:12 - browse：54932

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Juul spent big to court Black leaders to promote its e

focus

WSS

Cognito secures funding to test medical device for Alzheimer's

The Karikó problem: Lessons for funding basic research

Experts study whether long Covid risk adds up with each reinfection

Cognito secures funding to test medical device for Alzheimer's

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Cybersecurity threat forces Lurie Children's to take systems offline

focus

leisure time

knowledge

At least 13 dead in Texas as scorching temps continue

Will an HIV vaccine ever be a reality?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Covid misinformation case heads to Supreme Court

Alkermes shareholders re

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Bright Health sells Medicare Advantage business to Molina

What will Novo Nordisk's VC do with its influx of cash?

Peter Hotez and the public health issue of online harassment

Apple Vision Pro: A first look at health apps on the new VR headset

hotspot

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

European officials brace for rough respiratory virus season

Covid misinformation case heads to Supreme Court

Vertigo drug brings hope for rare neuron disorder, Niemann

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Health insurers' Q3 question: how much care are people getting?

focus

focus

hotspot

hotspot